Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in hiv-positive pregnant women

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2884-2893

  Santini Oliveira, Marilia ^a   De Cássia Elias, Rita ^b   Veloso, Valdiléa Gonçalves ^a   Cattani, Vitória Berg ^a   Yanavich, Carolyn ^c   Velasque, Luciane ^d   Torres, Thiago Silva ^a   Marins, Luana Monteiro Spindola ^a   Pilotto, José Henrique ^e   João, Esaú Custódio ^f   Gonçalves, José Carlos Saraiva ^b   Grinsztejn, Beatriz ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^e HOSPITAL GERAL DE FORTALEZA   (Brazil)

^f Hospital Federal dos Servidores do Estado   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN; NELFINAVIR; NEVIRAPINE; RITONAVIR; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; BACKACHE; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GASTROENTERITIS; GENITAL HERPES; GESTATIONAL AGE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MINIMUM INHIBITORY CONCENTRATION; MYOSITIS; NAUSEA; NEWBORN SEPSIS; OPEN STUDY; OTITIS; PATIENT COMPLIANCE; PLACENTA PREVIA; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PUERPERIUM; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SCABIES; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; SINUSITIS; SUPERFICIAL MYCOSIS; TABLET; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA BLEEDING; VAGINA CANDIDIASIS; VIRUS LOAD; VOMITING; WOUND INFECTION; BLOOD; HIV INFECTIONS; PREGNANCY; YOUNG ADULT;

ADULT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; PREGNANCY; RITONAVIR; YOUNG ADULT;

EID: 84898658017     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02599-13     Document Type: Article

References (44)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2011. Global report: UNAIDS Report on the Global AIDS Epidemic 2010. World Health Organization, Geneva, Switzerland.
2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J, Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1173-1180. http://dx.doi.org/10.1056/ NEJM199411033311801.
3. Shapiro D, Tuomala R, Pollack H, Burchett S, Read J, Cababasay M, McNamara J, Ciupak G. 2004. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery and viral load in 2895 US women (PACTG 367), abstr 99. Abstr. 11th Conf. Retroviruses Opportun. Infect., San Francisco, CA.
4. Sturt AS, Dokubo EK, Sint TT. 2010. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst. Rev. 2010:CD008440. http://dx.doi.org/10.1002/14651858.CD008440.
5. Buxton ILO. 2007. Farmacocinética e farmacodinâmica, p 1-20. In Brunton LL, Chabner BA, Knollmann BC (ed), As Bases Farmacológicas da Terapêutica de Goodman and Gilman, 11th ed. McGraw-Hill Ineramericana do Brasil Ltda., Rio de Janeiro, Brazil.
6. Ofotokun I, Chuck SK, Hitti JE. 2007. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend. Med. 4:106-119. http://dx.doi.org/ 10.1016/S1550-8579(07)80025-8.
7. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M. 2007. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J. Antimicrob. Chemother. 60:724-732. http://dx.doi.org/10.1093/jac/ dkm302.
8. Floridia M, Giuliano M, Palmisano L, Vella S. 2008. Gender differences in the treatment of HIV infection. Pharmacol. Res. 58:173-182. http://dx.doi.org/10.1016/j.phrs.2008.07.007.
9. Koren G. 2011. Pharmacokinetics in pregnancy; clinical significance. J. Popul. Ther. Clin. Pharmacol. 18:e523-e527.
10. Burger D, Siebers M, Hugen PW, Aarnoutse RE, Hekster YA, Koopmans PP. 2002. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J. Acquir. Immune Defic. Synd. 29:101-102.
11. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. 2004. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group 359. J. Infect. Dis. 189:1176-1184. http://dx.doi.org/10.1086/382754.
12. van der Leur MR, Burger DM, La Porte CJ, Koopmans PP. 2006. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther. Drug Monit. 28:650-653. http://dx.doi.org/10.1097/01.ftd.0000245681.12092.d6.
13. Mirochnick M, Capparelli E. 2004. Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. 43:1071-1087. http://dx.doi.org/10.2165/ 00003088-200443150-00002.
14. de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, Gilling-Smith C, Hawkins D, Low-Beer N, Lyall H, O'Shea S, Penn Z, Short J, Smith R, Sonecha S, Tookey P, Wood C, Taylor G. 2008. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 9:452-502. http://dx.doi.org/10.1111/j.1468-1293. 2008.00619.x.
15. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, Anzidei G, Fiscon M, Alberico S, Martinelli P, Placido G, Guaraldi G, Pinnetti C, Floridia M, Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. 2009. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 23:513-520. http://dx.doi.org/10.1089/apc. 2008.0263.
16. Ministério da Saúde, Departamento de DST, AIDS e Hepatites Virais. 2010. Guia de tratamento: recomendações para profilaxia da transmissão vertical do HIV e terapia antirretroviral em gestantes. Série Manuais, 46. 2012. Departamento de DST,AIDSe Hepatites Virais, Ministério da Saúde, Brasília, Brazil. http://www.aidstar- one.com/sites/default/files/Brazil-PMTCT-2010-tagged-0.pdf.
17. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. 2012. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, Office of AIDS Research Advisory Council, National Institutes of Health, Bethesda, MD. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. Accessed 20 February 2012.
18. Khuong-Josses MA, Azerad D, Boussaïri A, Ekoukou D. 2007. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin. Trials 8:254-255. http://dx.doi.org/ 10.1310/hct0804-254.
19. Best BM, Stek AM, Mirochnik M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV, International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team. 2010. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J. Acquir.ImmuneDefic. Syndr. 54:381-388. http://dx.doi.org/10.1097/QAI.0b013e3181d6c9ed.
20. Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M, PHPT-5 Team. 2010. Pharmacokinetics and virologic response of zidovudine/lopinavir/ ritonavir initiated during the third trimester of pregnancy. AIDS 24:2193-2200. http://dx.doi.org/10.1097/QAD. 0b013e32833ce57d.
21. Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, Back DJ, Brennan M, Connor EO, Boyle N, Fleming C, Coulter-Smith S, Khoo SH. 2011. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 12:166-173. http://dx.doi.org/10.1111/j.1468-1293.2010.00865.x.
22. Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, Phanuphak P, Chaithongwongwatthana S, Avihingsanon A, Phanuphak N. 2011. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS 25:1299-1303. http://dx.doi.org/10.1097/QAD.0b013e328347f7e9.
23. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133:21-30. http://dx.doi.org/10. 7326/0003-4819-133-1-200007040-00004.
24. Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. 2012. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob. Agents Chemother. 56:816-824. http://dx.doi.org/10.1128/AAC.05186- 11.
25. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. 2004. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0, December, 2004; clarification August 2009. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. http://www.mtnstopshiv.org/sites/default/files/attachments/DAIDS-AE- GradingTable-ClarificationAug2009-Final-[1].pdf.
26. Estrela RC, Ribeiro FS, Seixas BV, Suarez-Kurtz G. 2008. Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection. Rapid. Commun. Mass. Spectrom. 22:657-664. http://dx.doi.org/10.1002/rcm.3411.
27. La Porte CJL, Back D, Blaschke T, Boucher CAB, Fletcher CV, Flexner C, Gerber J, Kashuba ADM, Schapiro JM, Burger DM. 2006. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev. Antiviral Ther. 3:4-14.
28. Murphy RL, Brun S, Hicks C, Eron J, Gullick R, King M, White AC, Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-weeks results. AIDS 15:F1-F9. http://dx.doi.org/10.1097/00002030-200101050-00002.
29. van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D, HIV-NAT 019 Study Team. 2008. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J. Antimicrob. Chemother. 61:1145-1153. http://dx.doi.org/10.1093/jac/ dkn050.
30. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. 2006. Reduced lopinavir exposure during pregnancy. AIDS 20:1931-1939. http://dx.doi.org/10.1097/01.aids. 0000247114.43714.90.
31. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, Mills EJ, Gross R. 2011. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect. Disord. Drug Targets 11:167-174. http://dx.doi.org/10.2174/187152611795589663.
32. Kreitchmann R, Harris DR, Kakehasi F, Haberer JE, Cahn P, Losso M, Teles E, Pilotto JH, Hofer CB, Read JS, Study Team NISDI LILAC. 2012. Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS 26:486-495. http://dx.doi.org/10.1089/apc.2012.0013.
33. Patterson KB, Diamond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens M, Kashuba A. 2011. Pharmacokinetics of the LPV/r tablet in HIV-infected pregnant women: a longitudinal investigation of protein bound and unbound drug exposure with empiric dosage adjustment, abstr 645. Abstr. 18th Conf. Retroviruses Opportun. Infect., Boston, MA.
34. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, UK CHIC Steering Committee. 2010. Factors influencing lopinavir and atazanavir plasma concentration. J. Antimicrob. Chemother. 65:129-137. http://dx.doi.org/10.1093/jac/dkp408.
35. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C, Swiss HIV Cohort Study. 2009. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin. Pharmacol. Ther. 85:485-494. http://dx.doi.org/10.1038/clpt.2008.271.
36. Roca B. 2008. Pharmacogenomics of antiretrovirals. Recent Pat. Antiinfect. Drug Discov. 3:132-135. http://dx.doi.org/10.2174/ 157489108784746650.
37. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A, Swiss HIV Cohort Study. 2010. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet. Genomics 20:217-230.
38. Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. 2011. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther. Drug Monit. 33: 417-424. http://dx.doi.org/10.1097/FTD. 0b013e318225384f.
39. Urban TJ. 2010. Race, ethnicity, ancestry, and pharmacogenetics. Mt Sinai J. Med. 77:133-139. http://dx.doi.org/10.1002/msj.20168.
40. Pena SD, Bastos-Rodrigues L, Pimenta JR, Bydlowski SP. 2009. DNA tests probe the genomic ancestry of Brazilians. Braz. J. Med. Biol. Res. 42:870-876. http://dx.doi.org/10.1590/S0100-879X2009005000026.
41. Bolaffi G, Bracalenti R, Braham P, Gindro S (ed). 2003. Dictionary of race, ethnicity and culture. Sage Publications Ltd., London, England.
42. Gorowara M, Burger D, Hill A, Ruxrungtham K. 2010. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low-And middleincome countries. Curr. Opin. HIV AIDS 5:90-96. http://dx.doi.org/10.1097/COH.0b013e3283339caf.
43. Abbott Laboratories. 2012. Kaletra package insert. Abbott Laboratories, Abbott Park, IL. http://www.rxabbott.com/pdf/kaletratabpi.pdf. Accessed 20 February 2012.
44. Atkinson MJ, Petrozzino JJ. 2009. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDS 23:903-914. http://dx.doi.org/10.1089/apc.2009.0024.